ESPERITE N.V. (ESP) publishes its half-year report. Revenues, results and consolidated equity were impacted by adverse market conditions on the stem cell business.

CEO, Frédéric Amar, has converted part of his loan notes into 2.5 million shares to support the business and L1 Capital has continued financing the Company.

Amsterdam, The Netherlands – 30 June 2019
read more

ESPERITE (ESP): CEO Frederic Amar converts a portion of his Loan Note into 1.5 million shares.

Amsterdam, the Netherlands – 8 January 2018

read more

ESPERITE 2,154,000 shares exchanged today. Thank you for your interest in our company

Geneva, Switzerland – 23 February 2015

ESPERITE (ESP) 2’154’000 shares EXCHANGED TODAY.  THE COMPANY publishes this note of appreciation addressed to all the investors who massively increased the volume of transactions at the Euronext stock exchange today.

read more

Cryo-Save Group N.V.

Secondary listing Euronext Paris starts 7 July 2014, name change to Esperite N.V scheduled for 2 July 2014

Zutphen, the Netherlands – 30 June 2014

read more

Cryo-Save Group N.V.

La seconde cotation sur Euronext Paris débute le 7 juillet 2014, le changement de dénomination social en Esperite N.V. est fixé au 2 juillet 2014

Zutphen, Pays-Bas – le 30 juin 2014

read more

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, has been informed that via a block-trade Mr Johan Goossens, Chairman, sold 900,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) to Salveo Holding SA on 7 May 2013 and that at the same day Mr Marc Waeterschoot, co-founder and former Board Member of Cryo-Save, via a block-trade sold 1,460,000 Ordinary Shares to Salveo Holding SA, both at a price of €1.70. Salveo Holding SA has not contacted management of Cryo-Save about its intentions as a major shareholder.

read more

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, has been informed that Mr Arnoud van Tulder, Chief Executive Officer, purchased 4,752 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price of €1.24 on Wednesday 10 April 2013.

read more

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, has been informed that Mr Johan Goossens, Chairman, purchased 100,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price range between €1.19 and €1.24 on Friday 5 April and on Monday 8 April 2013.

read more

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that it has commenced a new tranche of its share buyback programme.

read more

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that it has completed the tranche of its share buyback programme as announced on 30 January 2013.

read more